TEMPEST THERAPEUTICS INC (TPST) Stock News

USA - NASDAQ:TPST - US87978U2078 - Common Stock

9.675 USD

+0.29 (+3.14%)

Last: 9/29/2025, 9:31:00 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TPST Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Benzinga - Mentions: COR PHR FBIO RLMD ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: Tempest Therapeutics

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Tempest Therapeutics

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Tempest Therapeutics

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

3 months ago - By: Tempest Therapeutics

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

4 months ago - By: Benzinga - Mentions: SSY HSDT WINT NCNA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

4 months ago - By: Tempest Therapeutics

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

4 months ago - By: Tempest Therapeutics

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

4 months ago - By: Zacks Investment Research - Mentions: LXRX CMMB

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

4 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

5 months ago - By: Tempest Therapeutics

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Tempest Therapeutics

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Tempest Therapeutics

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

5 months ago - By: Tempest Therapeutics

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

5 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

5 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

6 months ago - By: Stocktwits

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

6 months ago - By: Tempest Therapeutics

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

6 months ago - By: Tempest Therapeutics

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

6 months ago - By: Tempest Therapeutics

Tempest Reports Year End 2024 Financial Results and Provides Business Update

6 months ago - By: Tempest Therapeutics

Tempest Reports Year End 2024 Financial Results and Provides Business Update

6 months ago - By: Tempest Therapeutics

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

6 months ago - By: Tempest Therapeutics

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

7 months ago - By: Tempest Therapeutics

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

7 months ago - By: Tempest Therapeutics

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

8 months ago - By: Tempest Therapeutics

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

8 months ago - By: Tempest Therapeutics

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

8 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

9 months ago - By: Tempest Therapeutics

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

10 months ago - By: Tempest Therapeutics

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)